Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 18;216(6):1359–1376. doi: 10.1084/jem.20180660

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Medina et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — Macrophages produce DC chemoattractants that are reduced by imatinib. (A) RNaseq was performed in bulk tumors of Kit^V558Δ/+ mice treated with vehicle or imatinib for 3 wk. Graph shows expression of various chemokines (three mice/group). (B) Quantitative RT-PCR for chemokine mRNA expression in tumors of Kit^V558Δ/+ mice treated with imatinib (three to four mice/group). (C and D) CD45⁺ immune cells, CD45⁻Kit⁺ tumor cells, CD45⁻Kit⁻ stromal cells, and F4/80⁺ macrophages in untreated tumors of Kit^V558Δ/+ mice were isolated by magnetic beads. Quantitative RT-PCR of Ccl3 and Ccl4 mRNA expression was performed relative to Kit⁺ tumor cells (three mice/group). (E) Quantitative RT-PCR of Ccl3 and Ccl4 mRNA expression in tumors of Kit^V558Δ/+ mice treated with vehicle or imatinib for 2 wk (three to four mice/group, representative of two independent experiments). Data represent mean ± SEM; P values were calculated using a Student’s t test; *, P < 0.05.